Using MRD Status a Endpoint for Drug Approval

Event Description
While more myeloma specialists are accepting the importance of testing for minimal residual disease (MRD), it's harder to agree on what to do with those test results. One of the questions yet to answer is whether or not MRD results should be used as an endpoint on clinical trials.
Listen to Dr. Manni Mohyuddin as he shares his opinion on the subject. This kind of myeloma research can get us quicker to a cure!
Schedule & Agenda
Speakers & Moderators

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Dr. Mohyuddin completed his medical training at the prestigious Aga Khan University in Pakistan. He completed his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. After residency, he pursued Chief Residency at the University of Kansas, focusing on mechanisms of novel educational delivery and improving access to research for trainees. He completed his fellowship at the University of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma.
Join the Conversation
This event is part of the Lab Values and Testing group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org







Get the Latest Myelodysplastic Syndromes Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.